EyePoint Pharmaceuticals Inc (EYPT)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$9.39
Buy
$9.52
$-1.32 (-12.58%)
Prices updated at 16 Nov 2024, 00:37 EST
| Prices minimum 15 mins delay
Prices in USD
EyePoint Pharmaceuticals Inc, formerly pSivida Corp develops tiny, sustained-release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2022 | 2023 |
|---|---|---|
| 41m | 46m | |
| 33m | 41m | |
| -79m | -75m | |
| -190.65 | -163.13 | |
| -102m | -71m | |
| -97m | -69m | |
| Sales, General and administrative | 60m | 52m |
| Interest expenses | 3m | 1m |
| Provision for income taxes | - | 83,000 |
| Operating expenses | 112m | 116m |
| Income before taxes | -102m | -71m |
| Net income available to common shareholders | -102m | -71m |
| -2.74 | -1.82 | |
| Net interest income | -1m | 6m |
| Advertising and promotion | - | - |
| Net investment income, net | - | - |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | -2.74 | -1.82 |
| Free cash flow per share | -1.9535 | 0.2444 |
| Book value/share | 4.0005 | 1.1953 |
| Debt equity ratio | 0.366242 | 0.018421 |
Balance sheet
Year | 2022 | 2023 |
|---|---|---|
| Current assets | 173m | 345m |
| Current liabilities | 35m | 63m |
| Total capital | 126m | 266m |
| Total debt | 46m | 5m |
| Total equity | 96m | 266m |
| Total non current liabilities | - | - |
| Loans | 29m | - |
| Total assets | 180m | 355m |
| Total liabilities | - | - |
| Cash and cash equivalents | 96m | 281m |
| Common stock | 34m | 49m |
Cash flow
Year | 2022 | 2023 |
|---|---|---|
| Cash at beginning of period | 179m | 96m |
| Cash dividends paid | - | - |
| -67m | -2m | |
| Investments (gains) losses | -17m | -3m |
| 96m | 281m | |
| Net income | - | - |
| -65m | 2m | |
| -2m | -3m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
